Abstract
Importance COVID-19 has killed hundreds of thousands of people in the US and >1 million globally. Estimating the age-specific infection fatality rate (IFR) of SARS-CoV-2 for different populations is crucial for assessing the fatality of COVID-19 and for appropriately allocating limited vaccine supplies to minimize mortality.
Objective To estimate IFRs for COVID-19 in New York City and compare them to IFRs from other countries.
Design, Setting, Participants We used data from a published serosurvey of 5946 individuals 18 years or older conducted April 19-28, 2020 with time series of COVID-19 confirmed cases and deaths for five age-classes from the New York City Department of Health and Mental Hygiene. We inferred age-specific IFRs using a Bayesian framework that accounted for the distribution of delay between infection and seroconversion and infection and death.
Main Outcome and Measure Infection fatality rate.
Results We found that IFRs increased approximately 77-fold with age, with a nearly linear increase on a log scale, from 0.07% (0.055%-0.086%) in 18-44 year olds to 5.4% (4.3%-6.3%) in individuals 75 and older. New York City IFRs were higher for 18-44 year olds and 45-64 year olds (0.58%; 0.45%-0.75%) than Spanish, English, and Swiss populations, but IFRs for 75+ year olds were lower than for English populations and similar to Spanish and Swiss populations.
Conclusions and Relevance These results suggest that the age-specific fatality of COVID-19 differs among developed countries and raises questions about factors underlying these differences.
Question How do age-specific infection fatality rates (IFR) for COVID-19 in the U.S. compare to other populations?
Findings We estimated age-specific IFRs of SARS-CoV-2 using seroprevalence data and deaths in New York City. IFRs increased more than 75-fold with age, from 0.07% in 18-45 year olds to 5.3% in individuals over 75. IFRs in New York City were higher than IFRs in England, Geneva, France and Spain for individuals younger than 64 years old, but similar for older individuals.
Meaning The age-specific fatality of COVID-19 varies significantly among developed nations for unknown reasons.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
DEB-1911853
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA - only publicly available data were used in this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data in the ms are publicly available and links are provided to these sources.
